ACM
VIR icon

ACT Capital Management’s Vir Biotechnology VIR Stock Holding History

ACT Capital Management’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$655K Hold
64,300
– – 0.43% 34
2026
Q1 		$576K Buy
+64,300
New +$512K 0.45% 26
2022
Q1 		– Sell
-58,000
Closed -$2.43M – 99
2021
Q4 		$2.43M Buy
+58,000
New +$2.27M 1.76% 13

Other funds holding VIR

Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
SAI
Savvy Advisors Inc New York $4.71B AUM 25.36% 1-Year Est. Return
Nordea Investment Management
Nordea Investment Management Stockholm, Sweden $123B AUM 38.85% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
Walleye Capital
Walleye Capital New York $28B AUM 44.22% 1-Year Est. Return
APMC
Alta Partners Management Company Jackson, Wyoming $127M AUM 230.85% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
OAM
OP Asset Management Helsinki $9.38B AUM 42.35% 1-Year Est. Return

ACT Capital Management's VIR Position: Q2 2026 in Review

ACT Capital Management held its Vir Biotechnology (VIR) position steady in Q2 2026 at 64,300 shares worth $655K. The position accounts for 0.43% of the portfolio, ranked #34.

ACT Capital Management first reported a position in VIR in Q4 2021 and has held it in 3 quarters since. The position peaked at $2.43M in Q4 2021. 61 funds tracked by Wall St. Rank hold VIR as of Q2 2026.

  • ACT Capital Management held 64,300 shares of Vir Biotechnology worth $655K as of Q2 2026.
  • ACT Capital Management left its Vir Biotechnology share count unchanged in Q2 2026.
  • Vir Biotechnology made up 0.43% of ACT Capital Management's portfolio in Q2 2026, its #34 holding.
  • ACT Capital Management first reported a position in Vir Biotechnology in Q4 2021 and has held it in 3 quarters since.
  • ACT Capital Management's Vir Biotechnology position peaked at $2.43M in Q4 2021.
  • 61 funds tracked by Wall St. Rank held Vir Biotechnology as of Q2 2026.

Based on ACT Capital Management's 13F filing for Q2 2026, filed 29 Jul 2026.